Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Non Operating Income (2017 - 2025)

Lipocine's Non Operating Income history spans 10 years, with the latest figure at $174208.0 for Q3 2025.

  • For Q3 2025, Non Operating Income fell 57.68% year-over-year to $174208.0; the TTM value through Sep 2025 reached $835060.0, down 32.6%, while the annual FY2024 figure was $1.2 million, 26.31% down from the prior year.
  • Non Operating Income reached $174208.0 in Q3 2025 per LPCN's latest filing, down from $198637.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $895754.0 in Q2 2022 to a low of -$3.8 million in Q2 2021.
  • Average Non Operating Income over 5 years is $48619.5, with a median of $291292.0 recorded in 2024.
  • The largest YoY upside for Non Operating Income was 632.02% in 2021 against a maximum downside of 155.07% in 2021.
  • A 5-year view of Non Operating Income shows it stood at -$159926.0 in 2021, then surged by 307.22% to $331401.0 in 2022, then fell by 5.96% to $311653.0 in 2023, then fell by 24.05% to $236704.0 in 2024, then decreased by 26.4% to $174208.0 in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Non Operating Income are $174208.0 (Q3 2025), $198637.0 (Q2 2025), and $225511.0 (Q1 2025).